Johnson & Johnson (JNJ)
Johnson & Johnson - New TECVAYLI®(teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
Johnson & Johnson - New TECVAYLI®(teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General